For example, in a case study published in JCO Precision Oncology, a patient with refractory osteosarcoma had genomic testing showing CDK6 amplification with no inactivating alterations or loss of RB1, leading the oncology team to choose combination ribociclib and gemcitabine treatment based on our phase I clinical trial(22). This evidence concerns the gene CDK6 and osteosarcoma.